Somatuline^® Depot (lanreotide) Injection is the only long acting acromegaly therapy that is ready-to-use in a prefilled syringe1,11

Delivers a full 28-day dose from a single ready-to-use syringe
Patient- and professional-friendly injection designed with patients in mind1
- Administered via the deep subcutaneous route
- Short needle length of 20 mm
- Small syringe volume of only 0.3 - 0.5 mL

Chart from Visual Aid
Somatuline^® Depot (lanreotide) Injection has a smaller syringe volume than octreotide LAR1,11 *

The only 28-day somatostatin analog that does not require reconstitution1,11

Simple, two-step injection procedure.

Hands Removing the Protective Parts

Step 1:
Take out the syringe and remove the plunger protection and needle cap

Hands Injecting Somatuline

Step 2:
Somatuline^® Depot (lanreotide) Injection should be injected via the deep subcutaneous route in the superior external quadrant of the buttock.

* Comparative clinical significance is unknown.

How to inject Somatuline^® Depot (lanreotide) Injection

Somatuline^® Depot (lanreotide) Injection is injected in an easy, two-step injection process.1 Learn more about injecting Somatuline^® Depot (lanreotide) Injection.

Powerful, long-term efficacy

Somatuline^® Depot (lanreotide) Injection may help your patients experience long-term reductions in GH and IGF-1 levels1 Discover the long-term efficacy of Somatuline^® Depot (lanreotide) Injection.

Who should take Somatuline^® Depot (lanreotide) Injection

Somatuline^® Depot (lanreotide) Injection is indicated for the long-term treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation. It is also for patients who cannot tolerate surgery or radiation.1 Find out more about who should take Somatuline^® Depot (lanreotide) Injection.

IMPORTANT SAFETY INFORMATION

Somatuline^® Depot (lanreotide) Injection (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline^® Depot (lanreotide) Injection may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline^® Depot (lanreotide) Injection 60mg.

There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are no always predictive of human responses, Somatuline^® Depot (lanreotide) Injection should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline^® Depot (lanreotide) Injection may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline^® Depot (lanreotide) Injection may reduce the intestinal absorption of co-administered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.

Please see Full Prescribing Information for additional important information.

Somatuline^® Depot (lanreotide) Injection IS MARKETED BY TERCICA, INC. AND MANUFACTURED BY IPSEN PHARMA BIOTECH (SIGNES, FRANCE).

Somatuline® Depot (lanreotide) Injection is the only long acting acromegaly therapy that is ready-to-use in a prefilled syringe1,11